PharmaRoth Labs, Inc. Announces Mexican Distributor Surpasses Sales Goal
April 16 2014 - 9:15AM
Marketwired
PharmaRoth Labs, Inc. Announces Mexican Distributor Surpasses Sales
Goal
Media Advertising Increases as Sales Growth Exceeds Contractual
Obligation
LAS VEGAS, NV--(Marketwired - Apr 16, 2014) - PharmaRoth Labs,
Inc. (OTC Pink: ROTH) (PINKSHEETS: ROTH), the exclusive producer,
marketer & distributor of Sucanon®, an oral Type-II Diabetes
treatment, announced today that Marcas de Renombre (MDR), the
company's exclusive distributor in Mexico has surpassed their first
year minimum sales goal. In addition, the company is pleased to
confirm that media advertising in Mexico is concurrently
increasing.
"I am very excited to announce that our distributor in Mexico
has exceeded the contractual obligation of $480,000 of purchased
product this quickly," said Luis Lopez, CEO of PharmaRoth. "The
Agreement called for this minimum to be bought in the initial year
in order to maintain exclusive status. The sales are media driven
and even though the approval for the advertising from the Ministry
took much longer than anticipated, sales has been accelerated now
that the budget from MDR towards Sucanon® has been increased to
meet the demand."
Lopez continues: "As previously announced, our proprietary Type
II Diabetes drug is being sold thru retail and wholesale channels
backed by aggressive media advertising all throughout Mexico. The
product has never enjoyed this level of availability in any market
before so it is hugely exciting to be able to provide a safe and
effective drug for those afflicted with such a serious
disease."
For further information regarding Sucanon®, please visit
PharmaRoth Labs, Inc. website at www.pharmaroth.com
About PharmaRoth
PharmaRoth Labs, Inc. (OTC Pink: ROTH) (PINKSHEETS: ROTH) is
focused on diabetes prevention and treatments. The Company holds
the intellectual property and all exclusive world-wide rights
related to the production, marketing, and distribution of Sucanon®,
an oral treatment for Type-II diabetes. Sucanon® is a member of a
class of diabetic medications called insulin sensitizers. Insulin
sensitizers lower blood sugar by increasing the muscle, fat and
liver's sensitivity to insulin. Insulin sensitizers are blood sugar
normalizing or euglycemic drugs that help return the blood sugar to
the normal range without the risk of low blood sugars. PharmaRoth's
strategy is to increase awareness, acceptance, and distribution of
Sucanon® globally.
Forward Looking Statements: Statements in this document contain
certain forward-looking statements within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, as amended. These statements are based on
many assumptions and estimates and are not guarantees of future
performance. These statements may involve known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements of PharmaRoth Labs, Inc. to be
materially different from future results, performance or
achievements expressed or implied by such forward-looking
statements. PharmaRoth Labs, Inc. assumes no obligation to publicly
update or revise these forward-looking statements for any reason,
or to update the reasons actual results could differ materially
from those anticipated in these forward-looking statements, even if
new information becomes available in the future. Our actual
results may differ materially from the results anticipated in these
forward-looking statements due to a variety of factors. There may
be other factors not mentioned above that may cause actual results
to differ materially from those projected in any forward-looking
statement. We assume no obligation to update any
forward-looking statements as a result of new information, future
events or developments, except as required by applicable securities
laws.
For Investor Relations contact: Michael Irving Paramount
Advisors, LLC (407) 878-5462 mike@parvise.com
PharmaRoth Labs (CE) (USOTC:ROTH)
Historical Stock Chart
From Aug 2024 to Sep 2024
PharmaRoth Labs (CE) (USOTC:ROTH)
Historical Stock Chart
From Sep 2023 to Sep 2024